A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | https://repositorio.unifesp.br/handle/11600/31528 https://dx.doi.org/10.1186/1471-244X-9-28 |
Resumo: | Background: Topiramate might be effective in the treatment of posttraumatic stress disorder (PTSD) because of its antikindling effect and its action in both inhibitory and excitatory neurotransmitters. Open-label studies and few controlled trials have suggested that this anticonvulsant may have therapeutic potential in PTSD. This 12-week randomized, double-blind, placebo-controlled clinical trial will compare the efficacy of topiramate with placebo and study the tolerability of topiramate in the treatment of PTSD.Methods and design: Seventy-two adult outpatients with DSM-IV-diagnosed PTSD will be recruited from the violence program of Federal University of São Paulo Hospital (UNIFESP). After informed consent, screening, and a one week period of wash out, subjects will be randomized to either placebo or topiramate for 12 weeks. the primary efficacy endpoint will be the change in the Clinician-administered PTSD scale (CAPS) total score from baseline to the final visit at 12 weeks.Discussion: the development of treatments for PTSD is challenging due to the complexity of the symptoms and psychiatric comorbidities. the selective serotonin reuptake inhibitors (SSRIs) are the mainstream treatment for PTSD, but many patients do not have a satisfactory response to antidepressants. Although there are limited clinical studies available to assess the efficacy of topiramate for PTSD, the findings of prior trials suggest this anticonvulsant may be promising in the management of these patients. |
id |
UFSP_300122d1793f55700bc15b751ead4006 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/31528 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Mello, Marcelo Feijó de [UNIFESP]Yeh, Mary Sau Ling [UNIFESP]Barbosa Neto, Jair [UNIFESP]Braga, Luciana Lorens [UNIFESP]Fiks, Jose Paulo [UNIFESP]Mendes, Deise Daniela [UNIFESP]Moriyama, Tais Silveira [UNIFESP]Valente, Nina Leao Marques [UNIFESP]Costa, Mariana Caddrobi Pupo [UNIFESP]Mattos, Patricia [UNIFESP]Bressan, Rodrigo Affonseca [UNIFESP]Andreoli, Sergio Baxter [UNIFESP]Mari, Jair de Jesus [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2016-01-24T13:52:33Z2016-01-24T13:52:33Z2009-05-29Bmc Psychiatry. London: Biomed Central Ltd, v. 9, 7 p., 2009.1471-244Xhttps://repositorio.unifesp.br/handle/11600/31528https://dx.doi.org/10.1186/1471-244X-9-28WOS000268083100002.pdf10.1186/1471-244X-9-28WOS:000268083100002Background: Topiramate might be effective in the treatment of posttraumatic stress disorder (PTSD) because of its antikindling effect and its action in both inhibitory and excitatory neurotransmitters. Open-label studies and few controlled trials have suggested that this anticonvulsant may have therapeutic potential in PTSD. This 12-week randomized, double-blind, placebo-controlled clinical trial will compare the efficacy of topiramate with placebo and study the tolerability of topiramate in the treatment of PTSD.Methods and design: Seventy-two adult outpatients with DSM-IV-diagnosed PTSD will be recruited from the violence program of Federal University of São Paulo Hospital (UNIFESP). After informed consent, screening, and a one week period of wash out, subjects will be randomized to either placebo or topiramate for 12 weeks. the primary efficacy endpoint will be the change in the Clinician-administered PTSD scale (CAPS) total score from baseline to the final visit at 12 weeks.Discussion: the development of treatments for PTSD is challenging due to the complexity of the symptoms and psychiatric comorbidities. the selective serotonin reuptake inhibitors (SSRIs) are the mainstream treatment for PTSD, but many patients do not have a satisfactory response to antidepressants. Although there are limited clinical studies available to assess the efficacy of topiramate for PTSD, the findings of prior trials suggest this anticonvulsant may be promising in the management of these patients.Universidade Federal de São Paulo, Dept Psychiat, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Psychiat, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Psychiat, São Paulo, BrazilWeb of Science7engBiomed Central LtdBmc PsychiatryA randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorderinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000268083100002.pdfapplication/pdf268190${dspace.ui.url}/bitstream/11600/31528/1/WOS000268083100002.pdf62202584a7a40108b1ef3a8a898a3cddMD51open accessTEXTWOS000268083100002.pdf.txtWOS000268083100002.pdf.txtExtracted texttext/plain36256${dspace.ui.url}/bitstream/11600/31528/2/WOS000268083100002.pdf.txt2cf8ba5024b9f03d10f212e9d9a9ab2bMD52open access11600/315282023-02-14 14:38:45.444open accessoai:repositorio.unifesp.br:11600/31528Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:30:04.343214Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
title |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
spellingShingle |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder Mello, Marcelo Feijó de [UNIFESP] |
title_short |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
title_full |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
title_fullStr |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
title_full_unstemmed |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
title_sort |
A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder |
author |
Mello, Marcelo Feijó de [UNIFESP] |
author_facet |
Mello, Marcelo Feijó de [UNIFESP] Yeh, Mary Sau Ling [UNIFESP] Barbosa Neto, Jair [UNIFESP] Braga, Luciana Lorens [UNIFESP] Fiks, Jose Paulo [UNIFESP] Mendes, Deise Daniela [UNIFESP] Moriyama, Tais Silveira [UNIFESP] Valente, Nina Leao Marques [UNIFESP] Costa, Mariana Caddrobi Pupo [UNIFESP] Mattos, Patricia [UNIFESP] Bressan, Rodrigo Affonseca [UNIFESP] Andreoli, Sergio Baxter [UNIFESP] Mari, Jair de Jesus [UNIFESP] |
author_role |
author |
author2 |
Yeh, Mary Sau Ling [UNIFESP] Barbosa Neto, Jair [UNIFESP] Braga, Luciana Lorens [UNIFESP] Fiks, Jose Paulo [UNIFESP] Mendes, Deise Daniela [UNIFESP] Moriyama, Tais Silveira [UNIFESP] Valente, Nina Leao Marques [UNIFESP] Costa, Mariana Caddrobi Pupo [UNIFESP] Mattos, Patricia [UNIFESP] Bressan, Rodrigo Affonseca [UNIFESP] Andreoli, Sergio Baxter [UNIFESP] Mari, Jair de Jesus [UNIFESP] |
author2_role |
author author author author author author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Mello, Marcelo Feijó de [UNIFESP] Yeh, Mary Sau Ling [UNIFESP] Barbosa Neto, Jair [UNIFESP] Braga, Luciana Lorens [UNIFESP] Fiks, Jose Paulo [UNIFESP] Mendes, Deise Daniela [UNIFESP] Moriyama, Tais Silveira [UNIFESP] Valente, Nina Leao Marques [UNIFESP] Costa, Mariana Caddrobi Pupo [UNIFESP] Mattos, Patricia [UNIFESP] Bressan, Rodrigo Affonseca [UNIFESP] Andreoli, Sergio Baxter [UNIFESP] Mari, Jair de Jesus [UNIFESP] |
description |
Background: Topiramate might be effective in the treatment of posttraumatic stress disorder (PTSD) because of its antikindling effect and its action in both inhibitory and excitatory neurotransmitters. Open-label studies and few controlled trials have suggested that this anticonvulsant may have therapeutic potential in PTSD. This 12-week randomized, double-blind, placebo-controlled clinical trial will compare the efficacy of topiramate with placebo and study the tolerability of topiramate in the treatment of PTSD.Methods and design: Seventy-two adult outpatients with DSM-IV-diagnosed PTSD will be recruited from the violence program of Federal University of São Paulo Hospital (UNIFESP). After informed consent, screening, and a one week period of wash out, subjects will be randomized to either placebo or topiramate for 12 weeks. the primary efficacy endpoint will be the change in the Clinician-administered PTSD scale (CAPS) total score from baseline to the final visit at 12 weeks.Discussion: the development of treatments for PTSD is challenging due to the complexity of the symptoms and psychiatric comorbidities. the selective serotonin reuptake inhibitors (SSRIs) are the mainstream treatment for PTSD, but many patients do not have a satisfactory response to antidepressants. Although there are limited clinical studies available to assess the efficacy of topiramate for PTSD, the findings of prior trials suggest this anticonvulsant may be promising in the management of these patients. |
publishDate |
2009 |
dc.date.issued.fl_str_mv |
2009-05-29 |
dc.date.accessioned.fl_str_mv |
2016-01-24T13:52:33Z |
dc.date.available.fl_str_mv |
2016-01-24T13:52:33Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Bmc Psychiatry. London: Biomed Central Ltd, v. 9, 7 p., 2009. |
dc.identifier.uri.fl_str_mv |
https://repositorio.unifesp.br/handle/11600/31528 https://dx.doi.org/10.1186/1471-244X-9-28 |
dc.identifier.issn.none.fl_str_mv |
1471-244X |
dc.identifier.file.none.fl_str_mv |
WOS000268083100002.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1186/1471-244X-9-28 |
dc.identifier.wos.none.fl_str_mv |
WOS:000268083100002 |
identifier_str_mv |
Bmc Psychiatry. London: Biomed Central Ltd, v. 9, 7 p., 2009. 1471-244X WOS000268083100002.pdf 10.1186/1471-244X-9-28 WOS:000268083100002 |
url |
https://repositorio.unifesp.br/handle/11600/31528 https://dx.doi.org/10.1186/1471-244X-9-28 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Bmc Psychiatry |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
7 |
dc.publisher.none.fl_str_mv |
Biomed Central Ltd |
publisher.none.fl_str_mv |
Biomed Central Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/31528/1/WOS000268083100002.pdf ${dspace.ui.url}/bitstream/11600/31528/2/WOS000268083100002.pdf.txt |
bitstream.checksum.fl_str_mv |
62202584a7a40108b1ef3a8a898a3cdd 2cf8ba5024b9f03d10f212e9d9a9ab2b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460299135778816 |